1,684 Eli Lilly and Company $LLY Shares Bought by Brady Family Wealth LLC

Brady Family Wealth LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 92.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,501 shares of the company’s stock after acquiring an additional 1,684 shares during the quarter. Brady Family Wealth LLC’s holdings in Eli Lilly and Company were worth $4,051,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of LLY. Paulson Wealth Management Inc. lifted its stake in shares of Eli Lilly and Company by 6.4% in the 3rd quarter. Paulson Wealth Management Inc. now owns 1,190 shares of the company’s stock valued at $1,377,000 after purchasing an additional 72 shares during the period. StrongBox Wealth LLC boosted its holdings in Eli Lilly and Company by 20.1% during the third quarter. StrongBox Wealth LLC now owns 6,761 shares of the company’s stock worth $7,824,000 after buying an additional 1,130 shares in the last quarter. MMA Asset Management LLC boosted its holdings in Eli Lilly and Company by 2.9% during the third quarter. MMA Asset Management LLC now owns 647 shares of the company’s stock worth $749,000 after buying an additional 18 shares in the last quarter. Platform Technology Partners boosted its holdings in Eli Lilly and Company by 13.9% during the third quarter. Platform Technology Partners now owns 3,678 shares of the company’s stock worth $4,256,000 after buying an additional 448 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. grew its position in Eli Lilly and Company by 27.5% during the third quarter. Quest 10 Wealth Builders Inc. now owns 139 shares of the company’s stock valued at $161,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported encouraging Phase 3 results for investigational retatrutide in people with knee osteoarthritis and obesity, including substantial weight and knee-pain reductions. New data also showed benefits from combining Zepbound with Taltz in adults with psoriatic arthritis and obesity, supporting the potential of Lilly’s obesity franchise across additional conditions. Lilly ACR Convergence data
• Positive Sentiment: Recent earnings momentum remains a support: Lilly beat Q3 estimates and raised its outlook, reinforcing expectations for strong demand for its medicines. Commentary also presents LLY as a potential defensive holding amid the technology selloff, which could attract investors seeking growth outside tech. LLY as a potential safe haven
• Negative Sentiment: Investors are also watching growing price competition in the GLP-1 market. Lower realized prices could temper the revenue and profit growth investors expect from Lilly’s highly valued obesity-drug business. GLP-1 price competition

Insider Activity at Eli Lilly and Company

In related news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $17,020,770. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,368.85 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. The stock has a market capitalization of $1.29 trillion, a PE ratio of 44.43, a P/E/G ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00. The company has a fifty day moving average of $1,211.30 and a two-hundred day moving average of $1,099.50.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business earned $7.02 earnings per share. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent analyst reports. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price objective for the company in a report on Tuesday, September 15th. Morgan Stanley upped their price objective on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, October 31st. Truist Financial restated a “buy” rating and set a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Argus lifted their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.